|

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

RECRUITINGPhase 2Sponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Started2026-10-16
Est. completion2028-10-16
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites

Summary

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
* Female or male aged 18 years and older at the time of enrollment.
* Not pregnant and not nursing.
* No active infection requiring parenteral antibiotic(s).
* Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib
* No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients).
* Patients who are able to understand and willing to sign the written informed consent form or patients who have impaired decision-making capacity but have a legally authorized representative who can consent on their behalf are eligible. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion Criteria:

* Concurrent use of another investigational drug or device for the daraxonrasib-induced skin toxicity (i.e., outside of study treatment) during, or within 4 weeks of study treatment.
* Patients receiving prednisone 10 mg/day or higher (or equivalent) at the time of randomization for indications other than daraxonrasib skin toxicity management.
* Patients receiving tetracyclines, ivermectin or other systemic medication that could mask daraxonrasib rash development.
* Pregnancy or planned pregnancy during the study period.
* Documented allergy to oral ivermectin and / or minocycline
* Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation.

Conditions3

CancerPancreatic CancerSkin Toxicities

Interventions6

Locations7 sites

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920
Allison Gordon, MD646-608-2339
Memorial Sloan Kettering Monmouth (Consent Only)
Middletown, New Jersey, 07748
Allison Gordon, MD646-608-2339
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, 07645
Allison Gordon, MD646-608-2339
Memorial Sloan Kettering Suffolk-Commack (Consent Only)
Commack, New York, 11725
Allison Gordon, MD646-608-2339
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604
Allison Gordon, MD646-608-2339

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.